Skip to main content

Table 1 Baseline demographic parameters and indicators included in the training and testing datasets

From: Unlocking treatment success: predicting atypical antipsychotic continuation in youth with mania

Variables

Training

(3,621)

Testing

(911)

Age (year)

15.2 ± 4.7a

14.8 ± 4.5

Male

2,021 (55.5%)b

520 (57.1%)

Anxiety disorder

899 (24.7%)

227 (24.9%)

Depression

1,058 (29.8%)

285 (31.3%)

Intellectual disability

353 (9.7%)

81 (8.9%)

Personality disorders

262 (7.2%)

70 (7.7%)

Somatic Symptom disorder

171 (4.7%)

31 (3.4%)

Substance use disorder

455 (12.5%)

110 (12.1%)

Other mental health disorders

870 (23.9%)

204 (22.5%)

SSRI/SNRIs

13,187 (21.2%)

3,325 (22.3%)

Anticholinergic drugs

16,333 (1.2%)

4,147 (0.9%)

MAO inhibitors

10,646 (5.5%)

2,669 (4.9%)

Neurological and neuromuscular diseases

138 [3.8%]

40 [4.4%]

Cardiovascular diseases

62 (1.7%)

17 (1.9%)

Renal and urological disorders

51 [1.4%]

11 [1.2%]

Gastrointestinal diseases

36 [1.0%]

12 [1.3%]

Metabolic disorders

145 [3.0%]

30 [3.3%]

Asthma

477 [13.1%]

120 [13.2%]

Diabetes mellitus

98 [2.7%]

26 [2.9%]

Number of any route visits for mental health

disorders

2.32 ± 2.41

2.70 ± 2.45

Number of inpatient visits for mental health disorders

0.50 ± 2.43

0.73 ± 3.19

Number of outpatient visits for mental health

disorders

3.44 ± 3.62

3.70 ± 3.49

Number of emergency room visits for mental health disorders

1.21 ± 2.81

1.40 ± 2.33

Number of any route visits for nonmental health disorders

17.52 ± 15.26

17.71 ± 13.93

Number of inpatient visits for nonmental health disorders

1.34 ± 2.41

1.30 ± 3.02

Number of outpatient visits for nonmental health disorders

18.70 ± 16.73

16.97 ± 17.60

Number of emergency room visits for nonmental health disorders

1.91 ± 1.76

1.87 ± 1.49

Continuous treatment

543 (14.9%)

129 (14.2%)

  1. a Values represent mean (standard deviation)
  2. b Values represent n (%)
  3. Abbreviations: MAO, monoamine oxidase inhibitor; ADHD, attention deficit hyperactivity disorder; SSRI, selective serotonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor